---
company: LifeMD, Inc.
ticker: LFMD
form: 8-K
filed: 2026-05-06
accession: 0001493152-26-021520
source: https://www.sec.gov/Archives/edgar/data/948320/000149315226021520/
---

# LifeMD (LFMD) earnings release, May 6, 2026

LifeMD, Inc. (LFMD) · Form 8-K, Item 2.02 · Filed 2026-05-06 · [SEC filing](https://www.sec.gov/Archives/edgar/data/948320/000149315226021520/)

Exhibit

99.1

LifeMD

Reports First Quarter 2026 Results

Conference call begins at 4:30 p.m. Eastern time today

NEW

YORK, May 6, 2026 — LifeMD, Inc.

(Nasdaq: LFMD), a leading platform for virtual primary care services, today reported financial results for the first quarter ended March 31, 2026.

Management

Commentary

“Q1 was a strong start to 2026. We added more than 42,000 net telehealth subscribers, the largest quarterly net addition in our history.

We ended the quarter with over 365,000 subscribers. In weight management, sign-ups increased approximately 120% sequentially from Q4, and we exited the quarter with strong momentum across all of our key growth areas,” said Justin Schreiber, Chairman and CEO of

LifeMD.

“LifeMD is no longer just a telehealth company focused on a handful of conditions. We are building what we believe can become one of the most important virtual healthcare platforms in the country — a trusted destination where patients can access care, medications, labs, insurance-supported services, and ongoing clinical support through one connected experience.

“Our platform is uniquely positioned to support both direct-to-consumer self-pay and insurance-covered programs, and we are seeing continued traction with strong unit economics across our insurance-sponsored offerings. As previously guided, we are on track to expand coverage to approximately 230 million lives this month and believe our benefits infrastructure will be a key driver of long-term growth.

“At the same time, our women’s health business delivered exceptional performance in the quarter, with strong retention and improved customer acquisition costs supporting scalable, high-quality growth. Looking ahead, we are energized by the momentum across the business, with multiple strategic partnerships and new product launches in men’s and women’s health expected in the coming months, positioning us to drive continued top-line growth and profitability throughout the year,” concluded Mr. Schreiber.

“The first quarter played out largely as we expected: strong subscriber momentum, following a planned step-up in patient acquisition spend, and the early benefits of platform efficiency beginning to show in our gross margin,” said Atul Kavthekar, Chief Financial Officer of LifeMD. “Revenue for the first quarter was $50.2 million, exceeding our guidance range of $48 million to $49 million, with nearly all revenue derived from recurring subscriptions. The number of active subscribers increased approximately 26% year-over-year to over

365,000 at quarter end, with over 42,000 net adds in Q1, the largest quarterly net addition in our history. We exited the quarter with

$34.5 million in cash, no debt, and a $30 million undrawn revolving credit facility that we put in place at the start of the year. Our balance sheet remains a strategic asset, providing ample flexibility to fund our expanding growth initiatives.”

First

Quarter 2026 Financial Highlights

All comparisons are with the first quarter of 2025 on a continuing operations basis (excluding WorkSimpli, which was divested on November 4, 2025, and is reported as discontinued operations for all periods presented). Non-GAAP financial measures referenced below are defined and reconciled to the most directly comparable GAAP measures at the end of this press release.

First

Quarter Key Performance Metrics

Financial

Guidance

For the second quarter of 2026, the Company expects:

For the full year 2026, the Company affirms its previously issued guidance:

Conference

Call

LifeMD’s management will host a conference call today at 4:30 p.m. Eastern time to discuss the Company’s financial results and outlook, and answer questions. Details for the call are as follows:

A live and archived webcast will be available in the Investors section of the Company’s website at ir.lifemd.com.

About

LifeMD, Inc.

LifeMD® is a leading provider of virtual primary care. LifeMD offers telemedicine, access to laboratory and pharmacy services, and specialized treatment across more than 200 conditions, including primary care, men’s and women’s health, weight management, and hormone therapy. The Company leverages a vertically integrated, proprietary digital care platform, a 50-state affiliated medical group, a state-of-the-art affiliated pharmacy, and a U.S.-based patient care center to increase access to high-quality and affordable care. For more information, please visit

LifeMD.com.

Cautionary

Note Regarding Forward Looking Statements

This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended; Section

21E of the Securities Exchange Act of 1934, as amended; and the safe harbor provision of the U.S. Private Securities Litigation Reform

Act of 1995. Forward-looking statements contained in this news release may be identified by the use of words such as: “believe,”

“expect,” “anticipate,” “project,” “should,” “plan,” “will,”

“may,” “intend,” “estimate,” predict,” “continue,” and “potential,” or, in each case, their negative or other variations or comparable terminology referencing future periods. Examples of forward-looking statements include, but are not limited to, statements regarding our financial outlook and guidance, short and long-term business performance and operations, future revenues and earnings, regulatory developments, legal events or outcomes, ability to comply with complex and evolving regulations, market conditions and trends, new or expanded products and offerings, growth strategies, underlying assumptions, and the effects of any of the foregoing on our future results of operations or financial condition.

Forward-looking statements are not historical facts and are not assurances of future performance. Rather, these statements are based on our current expectations,... (truncated) regarding future plans and strategies, projections, anticipated and unanticipated events and trends, the economy, and other future conditions, including the impact of any of the aforementioned on our future business. As forward-looking statements relate to the future, they are subject to inherent risk, uncertainties, and changes in circumstances and assumptions that are difficult to predict, including some of which are out of our control. Consequently, our actual results, performance, and financial condition may differ materially from those indicated in the forward-looking statements. These risks and uncertainties include, but are not limited to, “Risk Factors” identified in our filings with the Securities and Exchange Commission, including, but not limited to, our most recently filed Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and any amendments thereto. Even if our actual results, performance, or financial condition are consistent with forward-looking statements contained in such filings, they may not be indicative of our actual results, performance, or financial condition in subsequent periods.

Any forward-looking statement made in the news release is based on information currently available to us as of the date on which this release is made. We undertake no obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, except as may be required under applicable law or regulation.

Investor

Contact ir@lifemd.com

Media

Contact press@lifemd.com

Tables to Follow

++++++

## Financial statements

### Income Statement (Three Months Ended March 31, — (Unaudited))

| | Three Months Ended March 31, – 2026 | Three Months Ended March 31, – 2025 |
|---|---:|---:|
| Telehealth revenue, net | 50,162,956 | 50,887,899 |
| Cost of telehealth revenue | 5,925,499 | 8,136,462 |
| Gross profit | 44,237,457 | 42,751,437 |
| Expenses | Selling and marketing expenses | 29,874,860 | 22,272,924 |
| Expenses | General and administrative expenses | 15,176,355 | 14,340,151 |
| Expenses | Other operating expenses | 3,179,946 | 2,389,536 |
| Expenses | Customer service expenses | 3,139,305 | 3,071,494 |
| Expenses | Development costs | 1,796,063 | 1,859,049 |
| Expenses | Total expenses | 53,166,529 | 43,933,154 |
| Expenses | Operating loss from continuing operations | -8,929,072 | -1,181,717 |
| Expenses | Interest income (expense), net | 56,476 | -463,638 |
| Expenses | Loss from continuing operations before income taxes | -8,872,596 | -1,645,355 |
| Expenses | Net loss from continuing operations | -8,872,596 | -1,645,355 |
| Expenses | Net income from discontinued operations |  | 1,993,422 |
| Expenses | Net (loss) income | -8,872,596 | 348,067 |
| Expenses | Net income attributable to noncontrolling interests of discontinued operations |  | 531,845 |
| Expenses | Net loss attributable to LifeMD, Inc. | -8,872,596 | -183,778 |
| Expenses | Preferred stock dividends | -776,563 | -776,563 |
| Expenses | Net loss attributable to LifeMD, Inc. common stockholders | -9,649,159 | -960,341 |
| Basic (loss) earnings per share attributable to LifeMD, Inc. common stockholders | Continuing operations | -0.2 | -0.06 |
| Basic (loss) earnings per share attributable to LifeMD, Inc. common stockholders | Discontinued operations |  | 0.03 |
| Basic (loss) earnings per share attributable to LifeMD, Inc. common stockholders | Basic loss per share | -0.2 | -0.02 |
| Diluted (loss) earnings per share attributable to LifeMD, Inc. common stockholders | Continuing operations | -0.2 | -0.06 |
| Diluted (loss) earnings per share attributable to LifeMD, Inc. common stockholders | Discontinued operations |  | 0.03 |
| Diluted (loss) earnings per share attributable to LifeMD, Inc. common stockholders | Diluted loss per share | -0.2 | -0.02 |
| Weighted average number of common shares outstanding: | Basic | 47,336,060 | 43,135,778 |
| Weighted average number of common shares outstanding: | Diluted | 47,336,060 | 43,135,778 |

### Balance Sheet (March 31, 2026 — (Unaudited))

| | March 31, 2026 | December 31, 2025 |
|---|---:|---:|
| Current Assets | Cash | 34,478,137 | 36,786,318 |
| Current Assets | Accounts receivable | 9,855,117 | 9,305,277 |
| Current Assets | Product deposit | 331,525 | 320,217 |
| Current Assets | Inventory, net | 3,177,136 | 2,773,576 |
| Current Assets | Other current assets | 3,855,131 | 2,646,077 |
| Current Assets | Total Current Assets | 51,697,046 | 51,831,465 |
| Non-current Assets | Equipment, net | 2,260,437 | 2,444,717 |
| Non-current Assets | Right of use assets, net | 5,055,090 | 5,267,857 |
| Non-current Assets | Capitalized software, net | 10,881,678 | 10,604,946 |
| Non-current Assets | Intangible assets, net | 230,417 | 262,334 |
| Non-current Assets | Total Non-current Assets | 18,427,622 | 18,579,854 |
| Non-current Assets | Total Assets | 70,124,668 | 70,411,319 |
| Current Liabilities | Accounts payable | 21,653,122 | 14,149,154 |
| Current Liabilities | Accrued expenses | 15,244,963 | 15,974,016 |
| Current Liabilities | Current operating lease liabilities | 670,825 | 642,422 |
| Current Liabilities | Deferred revenue | 12,016,840 | 10,807,773 |
| Current Liabilities | Total Current Liabilities | 49,585,750 | 41,573,365 |
| Long-term Liabilities | Non-current operating lease liabilities | 5,502,072 | 5,681,374 |
| Long-term Liabilities | Total Liabilities | 55,087,822 | 47,254,739 |
| Stockholders’ Equity | Series A Preferred Stock, $0.0001 par value; 1,610,000 shares authorized, 1,400,000 shares issued and outstanding as of March 31, 2026 and December 31, 2025 | 140 | 140 |
| Stockholders’ Equity | Common Stock, $0.01 par value; 100,000,000 shares authorized, 47,632,707 and 46,760,016 shares issued, 47,529,667 and 46,656,976 outstanding as of March 31, 2026 and December 31, 2025, respectively | 476,327 | 467,600 |
| Stockholders’ Equity | Additional paid-in capital | 252,976,314 | 251,455,616 |
| Stockholders’ Equity | Accumulated deficit | -238,252,234 | -228,603,075 |
| Stockholders’ Equity | Treasury stock, 103,040 shares, at cost, as of March 31, 2026 and December 31, 2025 | -163,701 | -163,701 |
| Stockholders’ Equity | Total LifeMD, Inc. Stockholders’ Equity | 15,036,846 | 23,156,580 |
| Stockholders’ Equity | Total Liabilities and Stockholders’ Equity | 70,124,668 | 70,411,319 |

### Cash Flow (Three Months Ended March 31, — (Unaudited))

| | Three Months Ended March 31, – 2026 | Three Months Ended March 31, – 2025 |
|---|---:|---:|
| CASH FLOWS FROM OPERATING ACTIVITIES | Net (loss) income | -8,872,596 | 348,067 |
| CASH FLOWS FROM OPERATING ACTIVITIES | Less: Net income from discontinued operations |  | 1,993,422 |
| CASH FLOWS FROM OPERATING ACTIVITIES | Net loss from continuing operations | -8,872,596 | -1,645,355 |
| Adjustments to reconcile net loss from continuing operations to net cash provided by operating activities: | Amortization of debt discount |  | 100,444 |
| Adjustments to reconcile net loss from continuing operations to net cash provided by operating activities: | Amortization of capitalized software | 1,674,852 | 1,529,380 |
| Adjustments to reconcile net loss from continuing operations to net cash provided by operating activities: | Amortization of intangibles | 31,917 | 6,667 |
| Adjustments to reconcile net loss from continuing operations to net cash provided by operating activities: | Depreciation of fixed assets | 289,458 | 155,361 |
| Adjustments to reconcile net loss from continuing operations to net cash provided by operating activities: | Noncash operating lease expense | 212,767 | 269,888 |
| Adjustments to reconcile net loss from continuing operations to net cash provided by operating activities: | Stock compensation expense | 1,448,905 | 2,548,528 |
| Changes in Assets and Liabilities | Accounts receivable | -549,840 | -459,948 |
